Amnis Therapeutics Thrombectomy Device-First in Man (FIM) Safety and Performance Study

Overview

Prospective, single-arm, open label, Safety and Performance clinical investigation.

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2021

Detailed Description

The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke. Pre-CE mark clinical investigation. Population will be subjects with documented untreated, acute ischemic stroke with large vessel occlusion.

Interventions

  • Device: Thrombectomy Device
    • The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke

Arms, Groups and Cohorts

  • Experimental: Open arm
    • Thrombectomy device to be used to retrieve clot and restore blood flow.

Clinical Trial Outcome Measures

Primary Measures

  • All serious adverse events (notably at 24 hours ± 3 hrs post procedure or until alternative stroke treatment is initiated, whichever comes first).
    • Time Frame: 24 hours ± 3 hrs post procedure or until alternative stroke treatment is initiated, whichever comes first.
    • It will investigate whether the application of Amnis Thrombectomy device is a safe method, in acute stroke therapy, for obtaining recanalization of large vessels and with favorable patient outcome.
  • All cause mortality (90 days).
    • Time Frame: 3 months post-procedure
    • Determine the number of participants with treatment-related adverse events.

Secondary Measures

  • Arterial recanalization of the occluded target vessel in the immediate post-procedure angiogram.
    • Time Frame: Immediate post-procedure angiogram.
    • Arterial recanalization of the occluded target vessel as angiographically scored by a Thrombolysis in Cerebral Infarction (TICI) flow grade of 2b or greater in the immediate post-procedure angiogram.
  • Proportion of patients with rapid neurological improvement as determined by a NIHSS ≤4.
    • Time Frame: First 24 hours after treatment
    • Proportion of patients with rapid neurological improvement (more than 4 points on the NIHSS or NIHSS ≤4) during the first 24 hours after treatment.
  • Good functional clinical outcome as determine by a modified Rankin Scale score of 0-2.
    • Time Frame: First 24 hours after treatment.
    • Proportion of patients with rapid neurological improvement (more than 4 points on the NIHSS or NIHSS ≤4) during the first 24 hours after treatment.

Participating in This Clinical Trial

Inclusion Criteria

1. Aged18-85years.

2. Subject who is contraindicated or failed (when the physician withdraws the tPA per physician discretion) intravenous tissue plasminogen activator (t-PA) therapy given at local institutions or within national practice. Failed means that the physician does not continue with IV tPA after thrombolysis; there is still an occlusion with TICI that is </= 1 as the relevant inclusion criteria.

3. Subject is able to be treated within 8 hours of stroke symptoms onset with minimum of one deployment of the Amnis Thrombectomy Device.

4. NIHSS score ≥8.

5. Pre-stroke mRS (modified Rankin Scale) score of 0 to 1.

6. Thrombolysis in cerebral infarction (TICI) ≤1 and causative occlusion of the M1 or M2 portion of the MCAs, anterior cerebral arteries, vertebral arteries, basilar artery ,or posterior cerebral arteries (P1 o rP2), confirmed by CT or MR angiography that is accessible to the Amnis thrombectomy device (i.e. according to IFU; 2-5.5 mm).

7. ASPECTS of ≥6 based on CT or MRI that was performed within 60 min prior to the start of endovascular procedure.

8. Subject or subject's legal guardian where regulations permit, signs the Patient Informed Consent and agrees that subject will attend follow-up visits.

Exclusion Criteria

1. Rapid neurological improvement prior to or at time of treatment suggesting resolution of signs/symptoms of stroke.

2. Estimated time of symptom onset.

3. Baseline NIHSS score <8.

4. BaselineNIHSS score ≥30 or state of coma.

5. Baseline pre-stroke mRS score >1.

6. Baseline Thrombolysis in cerebral infarction (TICI) > 2a.

7. Known serious sensitivity to radiographic contrast agent.

8. Arterial tortuosity, pre-existing stent and/o rother arterial disease that would prevent the device from reaching the target vessel.

9. Evidence of a moderate/large core defined as extensive early ischemic changes of Alberta Stroke Program Early CT score (ASPECTS) <6.

Co-morbid conditions:

10. Elevated blood pressure(systolic>185 mm Hg or diastolic >110 mm Hg)

11. Use of warfarin anticoagulation with INR >3.0.

12. Platelet count <30,000/mm³.

13. Blood glucose concentration <50 mg/dL (2.7 mmol/L).

14. CT/MRI imaging demonstrate smultilobar infarction (hypodensity >1/3 cerebral hemisphere).

15. CT or MRI evidence of mass effect, signs of hemorrhage, arteriovenous malformation or aneurysm or intra-cranial tumor (except small meningioma).

16. Angiographic evidence of carotid dissection, complete cervical carotid occlusions or vasculitis.

17. Clinical Symptoms or CT/MRI imaging suggest subarachnoid hemorrhage.

18. Imaging evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g. inability to navigate to target lesion, moderate/large infarct with poor collateral circulation, etc.).

General – related to the protocol or device:

19. Known sensitivity to nickel, titanium metals or their alloys.

20. Subject who requires hemodialysis or peritoneal dialysis, or who has a contraindication to an angiogram for whatever reason.

21. Current participation in another investigational drug or device study.

22. Female who is pregnant or lactating or has a positive pregnancy test at time of admission.

23. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than four alcoholic drinks per day).

24. Subject has a life expectancy of <90 days.

25. Subject with a comorbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Amnis Therapeutics
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Tommy Andersson, M.D.; Ph.D., Principal Investigator, Karolinska Institute, Neuroradiology Clinic, Stockholm, Sweden
  • Overall Contact(s)
    • Alan Cohen, B.S.; B.Med., +32 473 865091, alanscohen@skynet.be

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.